GSK2239633A
CAS No. 1240516-71-5
GSK2239633A ( —— )
产品货号. M26236 CAS No. 1240516-71-5
GSK2239633A 是 CC 趋化因子受体 4 (CCR4) 的变构拮抗剂,[125I]-TARC 与人 CCR4 结合的 pIC50 为 7.96。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1037 | 有现货 |
|
| 10MG | ¥1725 | 有现货 |
|
| 25MG | ¥3686 | 有现货 |
|
| 50MG | ¥5443 | 有现货 |
|
| 100MG | ¥7744 | 有现货 |
|
| 500MG | ¥15552 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称GSK2239633A
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述GSK2239633A 是 CC 趋化因子受体 4 (CCR4) 的变构拮抗剂,[125I]-TARC 与人 CCR4 结合的 pIC50 为 7.96。
-
产品描述GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.(In Vitro):GSK2239633A increases the CCL17-induced F-actin content of human CD4+ CCR4+ T cells with a pEC50 value of 8.79±0.22. GSK2239633A inhibits thymus- and activation-regulated chemokine-induced (TARC)-induced increases in the F-actin content of isolated human CD4+ CCR4+ T-cells with a pA2 of 7.11±0.29.(In Vivo):GSK2239633A demonstrates good pharmacokinetic data in preclinical animal studies with bioavailability in rats and beagle dogs of 85% and 97% respectively. Plasma GSK2239633A (i.v.) displays rapid, bi-phasic distribution and slow terminal elimination (13.5 h), suggesting that GSK2239633A is a low to moderate clearance drug. Blood levels of GSK2239633A(oral) reach Cmax rapidly (median tmax: 1.0-1.5 hours).
-
体外实验The GSK2239633A is an allosteric antagonist of human CCR4.GSK2239633A inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96±0.11 and also inhibits thymus- and activation-regulated chemokine-induced (TARC)-induced increases in the F-actin content of isolated human CD4+ CCR4+ T-cells with a pA2 of 7.11±0.29. The effect of GSK2239633A(Compound 3) on CCL17-induced increases in the F-actin content of human CD4+ CCR4+ T cells is measured. The pEC50 value is 8.79±0.22.
-
体内实验Following intravenous dosing, plasma GSK2239633A displays rapid, bi-phasic distribution and slow terminal elimination (t1/2: 13.5 hours), suggesting that GSK2239633A is a low to moderate clearance drug. Following oral dosing, blood levels of GSK2239633A reach Cmax rapidly (median tmax: 1.0-1.5 hours). Estimated GSK2239633A bioavailability is low with a maximum value determined of only 16%. GSK2239633A (Compound 9) demonstrates good pharmacokinetic data in preclinical animal studies (bioavailability in rats and beagle dogs 85% and 97% respectively).
-
同义词——
-
通路Autophagy
-
靶点CCR
-
受体Dopamine| Norepinephrine| serotonin
-
研究领域——
-
适应症——
化学信息
-
CAS Number1240516-71-5
-
分子量549.06
-
分子式C24H25ClN4O5S2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 250 mg/mL (455.32 mM)
-
SMILESCOc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Li R, Sahu S, Schachner M. Phenelzine, a cell adhesion molecule L1 mimetic small organic compound, promotes functional recovery and axonal regrowth in spinal cord-injured zebrafish. Pharmacol Biochem Behav. 2018 Aug;171:30-38.
产品手册
关联产品
-
CCR1 antagonist 6
CCR1 antagonist 6 (compound 16q) 是 CCR1 的一个拮抗剂,IC50 值为 3 nM。
-
J-113863
J-113863 也是人 CCR3 的有效拮抗剂(IC50 为 0.58 nM),但是小鼠 CCR3 的弱拮抗剂(IC50 为 460 nM)。 J-113863 对 CCR2、CCR4 和 CCR5 以及 LTB4 或 TNF-α 受体无活性。抗炎作用。 J-113863 是一种有效的选择性 CCR1 (CD18) 拮抗剂,IC50 值为 0.9 nM 和 5.8人和小鼠 CCR1 受体分别为 nM。
-
Maraviroc
Maraviroc 是 MIP-1α、MIP-1β 和 RANTES 的 CCR5 拮抗剂,IC50 分别为 3.3 nM、7.2 nM 和 5.2 nM。
021-51111890
购物车()
sales@molnova.cn

